Evidence map›Paper›PMID 39168064›Full record

ArticleCytokine2024

Poly I:C vaccination drives transient CXCL9 expression near B cell follicles in the lymph node through type-I and type-II interferon signaling.

Alexander G Ball, Katerina Morgaenko, Parastoo Anbaei, Sarah E Ewald, Rebecca R Pompano

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytokine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Alexander G BallDepartment of Microbiology Cancer Biology and Immunology, University of Virginia, Charlottesville, VA 22903, USA; Carter Immunology Center and UVA Cancer Center, University of Virginia, Charlottesville, VA 22903, USA.
Katerina MorgaenkoDepartment of Biomedical Engineering, University of Virginia School of Engineering and Applied Sciences, Charlottesville, VA 22904, USA.
Parastoo AnbaeiDepartment of Chemistry, University of Virginia College of Arts and Sciences, Charlottesville, VA 22904, USA.
Sarah E EwaldDepartment of Microbiology Cancer Biology and Immunology, University of Virginia, Charlottesville, VA 22903, USA; Carter Immunology Center and UVA Cancer Center, University of Virginia, Charlottesville, VA 22903, USA.
Rebecca R PompanoDepartment of Biomedical Engineering, University of Virginia School of Engineering and Applied Sciences, Charlottesville, VA 22904, USA; Department of Chemistry, University of Virginia College of Arts and Sciences, Charlottesville, VA 22904, USA; Carter Immunology Center and UVA Cancer Center, University of Virginia, Charlottesville, VA 22903, USA. Electronic address: rrp2z@virginia.edu.

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Dina Gould Halme · 1987 to 2026
$72.1M
Multi-organ culture and pumping systems for ex vivo models of immunity in hybrid tissue-chipsR01AI174207 · NIAID · UNIVERSITY OF VIRGINIA · PI Rebecca R Pompano · 2023 to 2026
$2.4M
Modeling immunity with a hybrid lymph node tissue-chipR01AI131723 · NIAID · UNIVERSITY OF VIRGINIA · PI POMPANO, REBECCA R · 2018 to 2022
$2.3M
NCI NIH HHS P30 CA044579NIAID NIH HHS R01 AI131723NIAID NIH HHS R01 AI174207
6 · The paper itself

Abstract

Subunit vaccines drive immune cell-cell interactions in the lymph node (LN), yet it remains unclear how distinct adjuvants influence the chemokines responsible for this interaction in the tissue. Here, we tested the hypothesis that classic Th1-polarizing vaccines elicit a unique chemokine signature in the LN compared to other adjuvants. Polyinosinic:polycytidylic acid (Poly I:C) vaccination resulted in dynamic upregulation of CXCL9 that was localized in the interfollicular region, a response not observed after vaccination with alum or a combination of alum and poly I:C. Experiments using in vivo mouse models and live ex vivo LN slices revealed that poly I:C vaccination resulted in a type-I IFN response in the LN that led to the secretion of IFNγ, and type-I IFN and IFNγ were required for CXCL9 expression in this context. CXCL9 expression in the LN was correlated with an IgG2c antibody polarization after vaccination; however, genetic depletion of the receptor for CXCL9 did not prevent the development of this polarization. Additionally, we measured secretion of CXCL9 from ex vivo LN slices after stimulation with a variety of adjuvants and confirmed that adjuvants that induced IFNγ responses also promoted CXCL9 expression. Taken together, these results identify a CXCL9 signature in a suite of Th1-polarizing adjuvants and determined the pathway involved in driving CXCL9 in the LN, opening avenues to target this chemokine pathway in future vaccines.

Indexed as

B-LymphocytesChemokine CXCL9Interferon-gammaInterferon Type ILymph NodesMice, Inbred C57BLPoly I-CSignal TransductionVaccinationAdjuvants, ImmunologicAnimalsFemaleMiceTh1 CellsAdjuvants, ImmunologicChemokine CXCL9Cxcl9 protein, mouseInterferon-gammaInterferon Type IPoly I-CAntibodyExtrafollicularInterferon gamma-induced protein 10 (IP-10)Monokine induced by gamma interferon (MIG)PolarizationTissue slices

Identifiers

PMID39168064
PMCPMC11428038

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.